Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.
Age
18–45
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP.
Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT).
Participant is ≤12 months postpartum at screening and Day 1.
You may not be if
Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD.
Participant has active psychosis per investigator assessment.
Participant has a medical history of nonfebrile seizures.
Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
